CDKN2A and Miyoshi myopathy: However, although CM has a much higher CDKN2A loss than MM, MM tends to show a greater frequency of CCND1 and CDK4 amplification (120, 122), implying CDK4 blocking agents may achieve a desired anti-tumor effect on MM.